// App-Quantinova.ai

: Risk Factors for Edoxaban‐related Gastrointestinal Bleeding in Patients with Gastrointestinal Cancer: Results from the Hokusai VTE Cancer Study

Researchers

Presenter

  • F.T.M. Bosch

Principal Investigators

  • N. vanEs

  • M. Di Nisio

  • N. Kraaijpoel

  • F.I. Mulder

  • M. Carrier

  • A. Segers

  • M.A. Grosso

  • J.I. Weitz

  • G.E. Raskob

  • P. Verhamme

  • H.R. Bller

Medical Centers

  • Amsterdam Cardiovascular Sciences, Amsterdam UMC, location AMC, Dept. of Vascular Medicine, Amsterdam, the Netherlands

  • Tergooi Hospitals, Department of Internal Medicine, Hilversum, the Netherlands

  • Gabriele D'Annunzio University, Department of Medicine and Ageing Sciences, Chieti, Italy

  • Ottawa Hospital Research Institute, Department of Medicine, Ottawa, Canada

  • ITREAS, Academic Research Organization, Amsterdam, the Netherlands

  • Daiichi Sankyo Pharma Development, Clinical Development, Basking Ridge, United States

  • McMaster University, Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada

  • University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City, United States

  • University Hospitals Leuven, the Department of Vascular Medicine and Hemostasis, Leuven, Belgium

Locations

  • Netherlands

  • Italy

  • Canada

  • United States

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Gastrointestinal bleeding

  • Gastric Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Edoxaban

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved